Thomas Beck, M.D.

In Memoriam

About

In Loving Memory of Thomas Russell Beck, M.D.
August 3, 1949 – May 25, 2020

It is with a profound and deep sense of sadness that F-Prime Capital says goodbye to Executive Partner Tom Beck. Tom was an essential and beloved friend and colleague to us all. We will greatly miss Tom’s expertise, wisdom, rolled-up-sleeves hands-on hard work, avuncular guidance, generosity, sense of humor and indefatigable bon homie that he maintained to the very end. Through his work, Tom made a big impact on the biotechnology industry, and an even bigger impact on all of us.

  • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. Learn more at www.aclaristx.com.

  • Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Suzhou, China

    • Year Invested

      2011

    • Team

  • Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Learn more at www.arvelletx.com.

  • CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.

  • Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ:RARE).

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Cambridge, MA

    • Year Invested

      2013

    • Team

  • Mersana Therapeutics (NASDAQ:MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines. Learn more at www.mersana.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2005

    • Team

  • Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including pain, cough and itch.  Learn more at www.nociontx.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Cambridge, MA

    • Year Invested

      2019

    • Team

  • Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company, is developing innovative therapies for neuropsychiatric disorders. Learn more at www.promentispharma.com.

    • Category

      • Therapeutics
    • Status

      • Private
    • Location

      Milwaukee, Wisconsin

    • Year Invested

      2016

    • Team

  • Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Newark, NJ

    • Year Invested

      2013

    • Team

  • Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.

     

  • Vicept Therapeutics is a dermatology specialty pharmaceutical company developing a topical prescription product for the treatment of the chronic skin condition, Rosacea. Vicept Therapeutics was acquired by Allergan.

     

  • Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Learn more at www.xiliotx.com.